Cardiovascular Manifestations of COVID-19
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75203
- Methodist Dallas Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Hospitalized patient
- Adult over 18 years
- Positive COVID-19 PCR Test
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Retrospective Cohort
Review electronic medical records of de-identified patients that tested positive for COVID-19 (using a PCR test) at Methodist Dallas Medical Center (MDMC) from June 2020 until December 2022
|
Chart review
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heart failure
Time Frame: March 2020 - June 2021
|
Presence or absence
|
March 2020 - June 2021
|
|
Tamponade
Time Frame: March 2020 - June 2021
|
Presence or absence
|
March 2020 - June 2021
|
|
Pericardial Effusion
Time Frame: March 2020 - June 2021
|
Presence or absence
|
March 2020 - June 2021
|
|
Myocarditis
Time Frame: March 2020 - June 2021
|
Presence or absence
|
March 2020 - June 2021
|
|
Pericarditis
Time Frame: March 2020 - June 2021
|
Presence or absence
|
March 2020 - June 2021
|
|
Arrythmias
Time Frame: March 2020 - June 2021
|
Presence or absence
|
March 2020 - June 2021
|
|
Troponin I
Time Frame: March 2020 - June 2021
|
Level
|
March 2020 - June 2021
|
|
N-terminal prohormone BNP
Time Frame: March 2020 - June 2021
|
Level
|
March 2020 - June 2021
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Stroke
Time Frame: March 2020 - June 2021
|
Presence or absence
|
March 2020 - June 2021
|
|
Myocardial infarction
Time Frame: March 2020 - June 2021
|
Type
|
March 2020 - June 2021
|
|
Shock
Time Frame: March 2020 - June 2021
|
Presence or absence
|
March 2020 - June 2021
|
|
Deep venous thrombosis
Time Frame: March 2020 - June 2021
|
Presence or absence
|
March 2020 - June 2021
|
|
Discharge disposition
Time Frame: March 2020 - June 2021
|
Location
|
March 2020 - June 2021
|
|
Primary diagnosis
Time Frame: March 2020 - June 2021
|
Diagnosis upon discharge
|
March 2020 - June 2021
|
|
Rate of ICU admission/transfer
Time Frame: March 2020 - June 2021
|
Rates
|
March 2020 - June 2021
|
|
Total hospital length of stay
Time Frame: March 2020 - June 2021
|
Number of Days
|
March 2020 - June 2021
|
|
ICU length of stay
Time Frame: March 2020 - June 2021
|
Number of Days
|
March 2020 - June 2021
|
|
Percentage of patients in cohort that had EKG testing or Echocardiography
Time Frame: March 2020 - June 2021
|
Percentage
|
March 2020 - June 2021
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Manavjot Sidhu, MD, Methodist Health System
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 030.CVS.2020.D
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
NCT06923137Active, not recruitingCOVID-19 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | COVID-19 Vaccines | SARS-CoV-2 Infection, COVID19 | COVID-19 Vaccination | SARS-CoV-2 Infection, COVID-19 | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 Infection
-
NCT06768697Not yet recruiting
-
NCT07110714RecruitingPost COVID-19 Condition | Post COVID-19 | Post COVID-19 Syndrome | Long COVID-19 Syndrome | Post COVID-19 Condition (PCC)
-
NCT07552779RecruitingRespiratory Tract Diseases | COVID-19 | Pneumonia | Lung Diseases | Coronavirus Disease 2019 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | Upper Respiratory Tract Infections | Respiratory Tract Infection | COVID-19 (Coronavirus Disease 2019)
-
NCT07445971RecruitingCOVID -19 | COVID-19 (Prevention)
-
NCT06156176RecruitingFatigue | Post-COVID-19 Syndrome | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19 | Long-COVID | Post-COVID Condition
-
NCT06294756CompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 Syndrome
-
NCT05839236Active, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated Stroke
-
NCT05817032RecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19
Clinical Trials on Chart review
-
NCT00507572TerminatedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm
-
NCT04296617CompletedMalignant Central Nervous System Neoplasm | Malignant Skull Base Neoplasm
-
NCT04557709WithdrawnHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm
-
NCT04089488CompletedIncidence and Prevalence of Cancer in People Living With HIV/AIDS at Cancer Centers in Latin AmericaHIV Infection | Malignant Neoplasm | Recurrent Malignant Neoplasm | Human Immunodeficiency Virus 1 Positive
-
NCT04778449Recruiting
-
NCT01627093Active, not recruitingHead and Neck Carcinoma
-
NCT01098630CompletedRecurrent Uterine Corpus Sarcoma | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Recurrent Cervical Carcinoma | Stage III Uterine Sarcoma | Stage IV Uterine Sarcoma | Stage I Uterine Sarcoma
-
NCT03868579CompletedMalignant Neoplasm | Malignant Respiratory Tract Neoplasm | Malignant Thoracic Neoplasm
-
NCT04087057Completed